The EMA at 20: Patients’ involvement in the activities of the EMA is a success story to be built upon
This article was originally published in Scrip
Great progress has been made, but more work will be needed to ensure that patients can continue to increase their involvement in the activities of the European Medicines Agency, say Yann Le Cam and Flaminia Macchia.
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.